Arcutis Biotherapeutics Past Earnings Performance

Past criteria checks 0/6

Arcutis Biotherapeutics's earnings have been declining at an average annual rate of -40.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 100% per year.

Key information

-40.7%

Earnings growth rate

34.9%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	100.0%
Return on equity	-295.6%
Net Margin	-439.8%
Next Earnings Update	14 May 2024

Recent past performance updates

Recent updates

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Sep 26

Revenue & Expenses Breakdown
Beta

How Arcutis Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ARQT Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	60	-262	185	111
30 Sep 23	49	-268	173	121
30 Jun 23	11	-331	161	164
31 Mar 23	6	-327	143	177
31 Dec 22	4	-311	122	182
30 Sep 22	1	-311	104	201
30 Jun 22	0	-260	85	172
31 Mar 22	0	-235	69	165
31 Dec 21	0	-206	61	146
30 Sep 21	0	-169	49	120
30 Jun 21	0	-150	38	113
31 Mar 21	0	-144	32	134
31 Dec 20	0	-136	21	115
30 Sep 20	0	-114	17	99
30 Jun 20	0	-90	14	78
31 Mar 20	0	-63	9	34
31 Dec 19	0	-42	7	37
30 Sep 19	0	-35	5	31
30 Jun 19	0	-28	3	26
31 Mar 19	0	-23	2	21
31 Dec 18	0	-19	2	18

Quality Earnings: ARQT is currently unprofitable.

Growing Profit Margin: ARQT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ARQT is unprofitable, and losses have increased over the past 5 years at a rate of 40.7% per year.

Accelerating Growth: Unable to compare ARQT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARQT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: ARQT has a negative Return on Equity (-295.65%), as it is currently unprofitable.

Arcutis Biotherapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Arcutis Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Recent updates

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023

Consensus revenue estimates increase by 26%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

New minor risk - Financial position

Price target decreased by 8.5% to US$41.71

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Announces Zoryve® (Roflumilast) Cream 0.3% Included in Preferred Position on National Formularies for CVS Caremark

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Price target decreased by 9.2% to US$45.50

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Director exercised options and sold US$104k worth of stock

Director exercised options and sold US$88k worth of stock

Director exercised options and sold US$130k worth of stock

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Director exercised options and sold US$102k worth of stock

Forecast to breakeven in 2025

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for ZORYVE Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

Arcutis Biotherapeutics, Inc. Enrolls First Patient in Phase 1B Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. Announces the Publication of Positive Patient-Reported Outcome Itch Data from Its Phase 2B Study Evaluating Once-Daily Roflumilast Cream (0.3% and 0.15%) in Adults with Chronic Plaque Psoriasis

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream

Consensus forecasts updated

Arcutis Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Consensus revenue estimates fall by 12%

Consensus forecasts updated

Consensus forecasts updated

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Arcutis Biotherapeutics: A Name To Accumulate

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology Congress

Arcutis Biotherapeutics, Inc. (NasdaqGS:ARQT) completed the acquisition of Ducentis BioTherapeutics Limited from LifeArc Seed fund managed by LifeArc, Endowment Arm for approximately $430 million.

Arcutis Biotherapeutics, Inc. (NasdaqGS:ARQT) entered into an agreement to acquire Ducentis BioTherapeutics Limited for approximately $430 million.

Revenue & Expenses Breakdown
Beta